Back to search results

Individualized Targeted Therapy for Pancreatic Cancer After Surgery

This study is testing a personalized treatment approach for people with pancreatic cancer who have had surgery and are at high risk of their cancer coming back. The treatment involves a "Treatment Plan" that is specifically chosen for you based on your tumor's molecular profile (its unique genetic makeup), as decided by a team of experts called a Molecular Tumor Board (MTB). This personalized treatment will be given for about 12 weeks. To join, you must be at least 18 years old, have pancreatic cancer (not neuroendocrine type) that has been surgically removed, and have either received other treatments like chemotherapy or radiation, or be unable to receive them. The study aims to see how long you stay disease-free and to track any side effects for up to 12 months.

Study design
This is an open-label study, meaning both you and your doctors will know what treatment you are receiving. It plans to enroll 40 participants.
What's involved
You would receive a personalized treatment regimen for approximately 12 weeks. Your tumor tissue or blood will be analyzed to help determine this treatment.
Compensation
Not stated in the trial record.
Follow-up
The study will track how long you remain disease-free for six months and monitor for any side effects for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06228599

Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence

Recruiting
NAAges 18+InterventionalTreatment
Medical College of Wisconsin
~40 participants
Updated 2026-05-05 on ClinicalTrials.gov
What's tested:Treatment Plan

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Disease-free Survival
Measured over Six months
+1 more outcome measured

Conditions

Pancreas Cancer

Explore related trials

Pancreatic Carcinoma

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Mandana Kamgar, MD, MPH · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin
  • Razelle Kurzrock, MD · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin
  • Douglas Evans, MD · PRINCIPAL_INVESTIGATOR · Medical College of Wisconsin

Who to contact

Medical College of Wisconsin Cancer Center Clinical Trials Office
[email protected]
866-680-0505 · ext. 8900
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Not a female of childbearing potential (FCBP), defined as all female patients that were not in post-menopause for at least one year or are surgically sterile, OR
An FCBP must have a negative serum pregnancy test and agree to use at least one form of pregnancy prevention during the study for at least one month after treatment discontinuation unless otherwise noted by the agent(s) USPI, which the FCBP must follow.

What this trial measures

  • Disease-free SurvivalSix months

    The number of subjects exhibiting disease-free survival at six months. Disease-free survival is defined as the time from study therapy initiation until disease recurrence or death from any cause.

  • Adverse EventsUp to 12 months

    The number of clinically relevant Grade 3 to 4 adverse events and serious adverse events that are at least possibly related to the study therapy per investigator assessment.